XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]        
Royalty income $ 47,765 $ 46,826 $ 160,633 $ 171,630
Diagnostic service revenue 23,962 2,520 31,580 4,686
Other revenue 31,673 0 31,673 0
Total revenues 103,400 49,346 223,886 176,316
Costs and expenses:        
Cost of revenue 409,463 80,030 718,734 256,455
Research and development 4,076,414 2,684,157 7,284,478 4,881,816
Selling and marketing 3,129,036 1,915,850 6,186,588 2,710,503
General and administrative 2,468,732 2,001,516 6,472,979 3,807,501
Total operating expenses 10,083,645 6,681,553 20,662,779 11,656,275
Loss from operations (9,980,245) (6,632,207) (20,438,893) (11,479,959)
Net interest expense 274,909 381,252 612,529 764,721
Gain (loss) from change in fair value of derivative instruments — warrants 52,876 (3,175,754) 586,626 (5,122,482)
Other income (loss), net 0 9,179 0 12,747
Net loss and comprehensive loss (10,202,278) (10,180,034) (20,464,796) (17,354,415)
Preferred stock dividend (6,060) (6,060) (12,120) (12,120)
Net loss and comprehensive loss attributable to common stockholders $ (10,208,338) $ (10,186,094) $ (20,476,916) $ (17,366,535)
Net loss per common share - basic (in USD per share) $ (0.34) $ (0.41) $ (0.69) $ (0.75)
Net loss per common share - diluted (in USD per share) $ (0.34) $ (0.41) $ (0.70) $ (0.75)
Weighted average shares outstanding — basic 29,958,037 24,592,883 29,856,611 23,212,963
Weighted average shares outstanding — diluted 29,958,037 24,592,883 30,033,207 23,212,963